PortalPublikationenAutologous haematopoietic stem cell mobilisation in multiple...

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Standard

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. / Mohty, M; Hübel, K; Kröger, N; Aljurf, M; Apperley, J; Basak, G W; Bazarbachi, A; Douglas, K; Gabriel, I; Garderet, L; Geraldes, C; Jaksic, O; Kattan, M W; Koristek, Z; Lanza, F; Lemoli, R M; Mendeleeva, L; Mikala, G; Mikhailova, N; Nagler, A; Schouten, H C; Selleslag, D; Suciu, S; Sureda, A; Worel, N; Wuchter, P; Chabannon, C; Duarte, R F.

in: BONE MARROW TRANSPL, Jahrgang 49, Nr. 7, 01.07.2014, S. 865-72.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mohty, M, Hübel, K, Kröger, N, Aljurf, M, Apperley, J, Basak, GW, Bazarbachi, A, Douglas, K, Gabriel, I, Garderet, L, Geraldes, C, Jaksic, O, Kattan, MW, Koristek, Z, Lanza, F, Lemoli, RM, Mendeleeva, L, Mikala, G, Mikhailova, N, Nagler, A, Schouten, HC, Selleslag, D, Suciu, S, Sureda, A, Worel, N, Wuchter, P, Chabannon, C & Duarte, RF 2014, 'Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation', BONE MARROW TRANSPL, Jg. 49, Nr. 7, S. 865-72. https://doi.org/10.1038/bmt.2014.39

APA

Mohty, M., Hübel, K., Kröger, N., Aljurf, M., Apperley, J., Basak, G. W., Bazarbachi, A., Douglas, K., Gabriel, I., Garderet, L., Geraldes, C., Jaksic, O., Kattan, M. W., Koristek, Z., Lanza, F., Lemoli, R. M., Mendeleeva, L., Mikala, G., Mikhailova, N., ... Duarte, R. F. (2014). Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. BONE MARROW TRANSPL, 49(7), 865-72. https://doi.org/10.1038/bmt.2014.39

Vancouver

Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. BONE MARROW TRANSPL. 2014 Jul 1;49(7):865-72. https://doi.org/10.1038/bmt.2014.39

Bibtex

@article{1e3a1b3d3c4d4c75bf94ff92f14651da,
title = "Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation",
abstract = "Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.",
author = "M Mohty and K H{\"u}bel and N Kr{\"o}ger and M Aljurf and J Apperley and Basak, {G W} and A Bazarbachi and K Douglas and I Gabriel and L Garderet and C Geraldes and O Jaksic and Kattan, {M W} and Z Koristek and F Lanza and Lemoli, {R M} and L Mendeleeva and G Mikala and N Mikhailova and A Nagler and Schouten, {H C} and D Selleslag and S Suciu and A Sureda and N Worel and P Wuchter and C Chabannon and Duarte, {R F}",
year = "2014",
month = jul,
day = "1",
doi = "10.1038/bmt.2014.39",
language = "English",
volume = "49",
pages = "865--72",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

AU - Mohty, M

AU - Hübel, K

AU - Kröger, N

AU - Aljurf, M

AU - Apperley, J

AU - Basak, G W

AU - Bazarbachi, A

AU - Douglas, K

AU - Gabriel, I

AU - Garderet, L

AU - Geraldes, C

AU - Jaksic, O

AU - Kattan, M W

AU - Koristek, Z

AU - Lanza, F

AU - Lemoli, R M

AU - Mendeleeva, L

AU - Mikala, G

AU - Mikhailova, N

AU - Nagler, A

AU - Schouten, H C

AU - Selleslag, D

AU - Suciu, S

AU - Sureda, A

AU - Worel, N

AU - Wuchter, P

AU - Chabannon, C

AU - Duarte, R F

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

AB - Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

U2 - 10.1038/bmt.2014.39

DO - 10.1038/bmt.2014.39

M3 - SCORING: Journal article

C2 - 24686988

VL - 49

SP - 865

EP - 872

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -